Compare PLPC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | TNGX |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | PLPC | TNGX |
|---|---|---|
| Price | $277.66 | $13.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 117.4K | ★ 2.8M |
| Earning Date | 03-12-2026 | 02-27-2026 |
| Dividend Yield | ★ 0.30% | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 7.55 | N/A |
| Revenue | ★ $663,346,000.00 | $66,501,000.00 |
| Revenue This Year | $16.31 | $52.63 |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | $36.95 | ★ N/A |
| Revenue Growth | 15.93 | ★ 53.29 |
| 52 Week Low | $118.99 | $1.03 |
| 52 Week High | $287.97 | $13.48 |
| Indicator | PLPC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 63.83 | 61.37 |
| Support Level | $270.20 | $12.12 |
| Resistance Level | $287.97 | $13.18 |
| Average True Range (ATR) | 12.94 | 0.79 |
| MACD | 1.03 | -0.02 |
| Stochastic Oscillator | 83.70 | 76.61 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.